Compare Cassava Sciences Inc (FLNA) vs Kinder Morgan Inc (KMI) Price & Performance

Filana Therapeutics (FLNA) trades at $0.82, down 6.77% today, amid bearish technical signals but with positive fundamental catalysts. The company shows improving quarterly EPS beats and a favorable EV/EBITDA of 1.03, though it remains unprofitable with negative cash flow. Recent FDA clearance for its epilepsy drug trial has generated optimism, reflected in strong analyst buy ratings (67% consensus).

The outlook balances clinical progress against financial strain. The FDA hold lift on simufilam provides a clear near-term catalyst for Phase 2a trials starting in 2027, supporting the bullish analyst view. However, high cash burn (-$33M net CF in 2025) and lack of revenue pose significant risks to sustainability, requiring careful monitoring of funding and trial milestones.

Kinder Morgan (KMI) trades at $31.82, down 1.06% on the day, with strong technical momentum indicated by bullish moving averages. The company demonstrates robust fundamentals with revenue growth from $15.1B in 2024 to $16.9B in 2025 and net income margins expanding to 19.31%. Recent earnings beats in Q4 2025 through Q2 2026 highlight operational strength, while a $6B-$7B growth pipeline supports future expansion in natural gas infrastructure.

KMI presents a compelling investment case with analyst consensus target of $37.20 offering 17% upside potential. The stock's 4% dividend yield and consistent cash flow generation provide income stability, though exposure to energy market volatility and high debt levels ($29.66B long-term debt) remain key risks. Wall Street sentiment is balanced with 47% buy ratings versus 50% hold recommendations.